|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Basic and Translational Investigations |
Brain Tumor Research Center of the Department of Neurological Surgery (T.O., L.J.H., R.A.S., K.R.L., D.F.D.) and Department of Pathology (A.W.B.), University of California San Francisco, San Francisco, CA 94143-0520; and Geron Corporation, Menlo Park, CA 94025 (S.M.G., K.P.); USA
2 Address correspondence to Dennis F. Deen, Brain Tumor Research Center, 505 Parnassus Ave., U-378, University of California San Francisco, San Francisco, CA 94143-0520, USA (ddeen{at}itsa.ucsf.edu).
Abstract
Telomerase is a ribonucleoprotein complex that elongates telomeric DNA and
appears to play an important role in cellular immortalization of cancers.
Because telomerase is expressed in the vast majority of malignant gliomas but
not in normal brain tissues, it is a logical target for glioma-specific
therapy. The telomerase inhibitor GRN163, a 13-mer oligonucleotide
N3'
P5' thio-phosphoramidate (Geron Corporation,
Menlo Park, Calif.), is complementary to the template region of the human
telomerase RNA subunit hTR. When athymic mice bearing U-251 MG human brain
tumor xenografts in their flanks were treated intratumorally with GRN163, a
significant growth delay in tumor size was observed (P < 0.01 in
all groups) as compared to the tumor size in mice receiving a mismatched
oligonucleotide or the carrier alone. We also investigated biodistribution of
the drug in vivo in an intracerebral rat brain-tumor model.
Fluorescein-labeled GRN163 was loaded into an osmotic minipump and infused
directly into U-251 MG brain tumors over 7 days. Examination of the brains
revealed that GRN163 was present in tumor cells at all time points studied.
When GRN163 was infused into intracerebral U-251 MG tumors shortly after their
implantation, it prevented their establishment and growth. Lastly, when rats
with larger intracerebral tumors were treated with the inhibitor, GRN163
increased animal survival times. Our results demonstrate that the
antitelomerase agent GRN163 inhibits growth of glioblastoma in vivo, exhibits
favorable intracerebral tumor uptake properties, and prevents the growth of
intracerebral tumors. These findings support further development of this
compound as a potential anticancer agent.
References
Burger, P.C., Scheithauer, B.W., and Vogel, F.S. (1990) Brain: Tumors. In: Surgical Pathology of the Nervous System and its Coverings. New York: Churchill Livingstone, pp. 193-196.
Chong, E.Y., Lam, P.Y., Poon, W.S., and Ng, H.K. (1998) Telomerase expression in gliomas including the nonastrocytic tumors. Hum. Pathol. 29,599 -603.[CrossRef][ISI][Medline]
Counter, C.C., Avilion, A.A., LeFeuvre, C.E., Stewart, N.G., Greider, C.W., Harley, C.B., and Bacchetti, S. (1992) Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 11,1921 -1929.[ISI][Medline]
Greider, C.W., and Blackburn, E.H. (1985) Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 43,405 -413.[CrossRef][ISI][Medline]
Gryaznov, S.M., and Letsinger, R.L. (1992) Synthesis
and properties of oligonucleotides containing aminodeoxythymidine units.
Nucleic Acids Res. 20,3403
-4309.
Gryaznov, S.M., Pongracz, K., Matray, T., Schultz R., Pruzan R., Aimi, J., Chin, A., Harley, C., Shea-Herbert, B., Shay, J., Oshima, Y., Asai, A., and Yamashita, Y. (2001) Telomerase inhibitors—oligonucleotide phosphoramidates as potential therapeutic agents. Nucleosides Nucleotides Nucleic Acids 20,401 -410.[CrossRef][ISI][Medline]
Hakin-Smith, V., Jellinek, D.A., Levy, D., Carroll, T., Teo, M., Timperley, W.R., McKay, M.J., Reddel, R.R., and Royds, J.A. (2003) Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 361,836 -838.[CrossRef][ISI][Medline]
Herbert, B.-S., Pongracz, K., Shay, J.W., and Gryaznov, S.M.
(2002) Oligonucleotide N3'P5' phosphoramidates
as efficient telomerase inhibitors. Oncogene
21,638
-642.[CrossRef][ISI][Medline]
Hiyama, E., Hiyama, K., Yokoyama, T., Matsuura, Y., Piatyszek, M.A., and Shay, J.W. (1995) Correlating telomerase activity levels with human neuroblastoma outcomes. Nature Med. 1, 249-255.[CrossRef][ISI][Medline]
Hollander, M., and Wolfe, D.A. (1973) Nonparametric Statistical Methods. New York: John Wiley & Sons, pp. 120-123.
Kim, N.W., Piatyszek, M.A., Prowse, K.R., Harley, C.B., West, M.D.,
Ho, P.L., Coviello, G.M., Wright, W.E., Weinrich, S.L., and Shay, J.W.
(1994) Specific association of human telomerase activity with
immortal cells and cancer. Science
266,2011
-2015.
Kondo, S., Kondo, Y., Li, G., Silverman, R.H., and Cowell J.K. (1998) Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene 16,3323 -3330.[CrossRef][ISI][Medline]
Langford, L.A., Piatyszek, M.A., Xu, R., Schold, S.C., Jr., and Shay, J.W. (1995) Telomerase activity in human brain tumours. Lancet 346,1267 -1268.[CrossRef][ISI][Medline]
Le, S., Zhu, J.J., Anthony, D.C., Greider, C.W., and Black, P.M. (1998) Telomerase activity in human gliomas. Neurosurgery 42,1120 -1125.[CrossRef][ISI][Medline]
Levin, V.A., Silver, P., Hannigan, J., Wara, W.M., Gutin, P.H., Davis, R.L., and Wilson, C.B. (1990) Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int. J. Radiat. Oncol. Biol. Phys. 18,321 -324.[ISI][Medline]
Lin, Y., Miyamoto, H., Fujinami, K., Uemura, H., Hosaka, M., Iwasaki, Y., and Kubota, Y. (1996) Telomerase activity in human bladder cancer. Clin. Cancer Res. 2, 929-932.[Abstract]
Mao, L., El-Naggar, A.K., Fan, Y.H., Lee, J.S., Lippman, S.M.,
Kayser, S., Lotan, R., and Hong, W.K. (1996) Telomerase activity
in head and neck squamous cell carcinoma and adjacent tissues.
Cancer Res. 56,5600
-5604.
Miller, P.J., Hassanein, R.S., Giri, P.G., Kimler, B.F., O'Boynick, P., and Evans, R.G. (1990) Univariate and multivariate statistical analysis of high-grade gliomas: The relationship of radiation dose and other prognostic factors. Int. Radiat. Oncol. Biol. Phys. 19,275 -280.
Mori, K., Tanaka, R., Onda, K., Tsumanuma, I., and Yoshimura, J. (1997) Expression of telomerase RNA, telomerase activity, and telomere length in human gliomas. Biochem. Biophys. Res. Commun. 239,830 -834.[CrossRef][ISI][Medline]
Mukai, S., Kondo, Y., Koga, S., Komata, T., Barna, B.P., and Kondo,
S. (2000) 2-5A antisense telomerase RNA therapy for intracranial
malignant gliomas. Cancer Res.
60,4461
-4467.
Ozawa, T., Wang, J., Hu, L.J., Lamborn, K.R., Bollen, A.W., and Deen, D.F. (1998) Characterization of human glioblastoma xenograft growth in athymic mice. In Vivo 12,369 -374.[ISI][Medline]
Ozawa, T., Wang, J., Hu, L.J., Bollen, A.W., Lamborn K.R., and Deen, D.F. (2002) Growth of human glioblastomas as xenografts in the brains of athymic rats. In Vivo 16, 55-60.[ISI][Medline]
Pongracz, K., and Gryaznov, S.M. (1999)
Oligonucleotide N3'P5' thio-phosphoramidates: Synthesis and
properties. Tetrahedron Lett.
40,7661
-7664.[CrossRef]
Recht, L., Fram, R.J., Strauss, G., Fitzgerald, T.J., Liepman, M., Lew, R., Kadish, S., Sherman, D., Wilson, J., Greenberger, J., Egan, P., and Silver, D. (1990) Preirradiation chemotherapy of supratentorial malignant primary brain tumors with intracarotid cis-platinum (CDDP) and i.v. BCNU. A phase II trial. Am. J. Clin. Oncol. 13,125 -131.[ISI][Medline]
Sano, T., Asai, A., Mishima, K., Fujimaki, T., and Kirino, T. (1998) Telomerase activity in 144 brain tumours. Br. J. Cancer 77,1633 -1637.[ISI][Medline]
Shibamoto, Y., Yamashita, J., Takahashi, M., Yamasaki, T., Kikuchi, H., and Abe, M. (1990) Supratentorial malignant glioma: An analysis of radiation therapy in 178 cases. Radiother. Oncol. 18,9 -17.[CrossRef][ISI][Medline]
Sommerfeld, H.J., Meeker, A.K., Piatyszek, M.A., Bova, G.S., Shay,
J.W., and Coffey, D.S. (1996) Telomerase activity: A prevalent
marker of malignant human prostate tissue. Cancer Res.
56,218
-222.
Sugino, T., Yoshida, K., Bolodeoku, J., Tahara, H., Buley, I., Manek, S., Wells, C., Goodison, S., Ide, T., Suzuki, T., Tahara, E., and Tarin, D. (1996) Telomerase activity in human breast cancer and benign breast lesions: Diagnostic applications in clinical specimens, including fine needle aspirates. Int. J Cancer 69,301 -306.[CrossRef][ISI][Medline]
Yu, G.L., Bradley, J.D., Attardi, M.L., and Blackburn, E.H. (1990) In vivo alteration of telomere sequences and senescence caused by mutated Tetrahymena telomerase RNAs. Nature 344,126 -132.[CrossRef][Medline]
This article has been cited by other articles:
|
|
 |
|
  R. Hashizume, T. Ozawa, S. M. Gryaznov, A. W. Bollen, K. R. Lamborn, W. H. Frey II, and D. F. Deen New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163 Neuro-oncol, April 1, 2008; 10(2): 112 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Jackson, C.-H. Zhu, V. Paulson, L. Watkins, Z. G. Dikmen, S. M. Gryaznov, W. E. Wright, and J. W. Shay Antiadhesive Effects of GRN163L--An Oligonucleotide N3'->P5' Thio-Phosphoramidate Targeting Telomerase Cancer Res., February 1, 2007; 67(3): 1121 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Hochreiter, H. Xiao, E. M. Goldblatt, S. M. Gryaznov, K. D. Miller, S. Badve, G. W. Sledge, and B.-S. Herbert Telomerase Template Antagonist GRN163L Disrupts Telomere Maintenance, Tumor Growth, and Metastasis of Breast Cancer. Clin. Cancer Res., May 15, 2006; 12(10): 3184 - 3192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. G. Dikmen, G. C. Gellert, S. Jackson, S. Gryaznov, R. Tressler, P. Dogan, W. E. Wright, and J. W. Shay In vivo Inhibition of Lung Cancer by GRN163L: A Novel Human Telomerase Inhibitor Cancer Res., September 1, 2005; 65(17): 7866 - 7873. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
